Advanced Micro Devices

Refresh delta (since 2026-09-25)

What changed

1. AMD agreed to buy World Labs for about $8.2B, all in stock. The 8-KForm 8-KA filing for something that happened between reports and matters enough to tell shareholders now. says: on 2026-09-26 AMD "entered into an Agreement and Plan of Merger … to acquire all of the equity interests in World Labs Technologies, Inc. … for a total purchase price of approximately $8.2 billion to be paid in shares of the Company's common stock … subject to customary adjustments" [SEC: 8-K, 2026-09-28, 0000002488-26-000182]. It was filed under Item 3.02 (unregistered sales of equity), not Item 1.01 or 2.01, and the filing has no exhibits: the merger agreement and a press release are not filed [SEC: filing index, 0000002488-26-000182].
2. The number of shares is not fixed yet. The filing says the count "is not known" and will be set by "the daily volume-weighted average price … over the ten (10) consecutive trading-day period ending on and including the second trading day immediately preceding the closing date" [SEC: 8-K, 2026-09-28, 0000002488-26-000182]. So the dollar value is fixed and the share count floats: a higher AMD price means fewer shares issued. The shares are issued privately under Section 4(a)(2) and/or Regulation D Rule 506, not in a public offering [same].
3. Dilution is under 1%. The latest 10-QForm 10-QThe quarterly version of the annual report. Lighter, and not audited. cover shows 1,632,475,042 shares outstanding as of 2026-07-29 [SEC: 10-Q, 2026-08-05, 0000002488-26-000123, cover page]. Illustrative share counts at actual closes:

. The real count is unknown until closing, and "customary adjustments" (cash, debt, working capital, likely) can move the $8.2B. The closing date is not in the filing. Press reports say "by end of 2026" and subject to regulatory approval. 4. Scale against what is already on the cap table. The OpenAI and Meta warrants are up to 320M shares combined, none vested at 2026-06-27 [SEC: 10-Q, 2026-08-05, 0000002488-26-000123, equity note; carried from prior dossier]. That is ~19.6% of shares outstanding. World Labs adds roughly one twenty-fifth of that. By market value the deal is ~0.8% of AMD. 5. The stock fell 3.6% on announcement day ($630.63 → $607.87, 2026-09-28) and has since risen to $645.86. No cause is attributed in a primary source; the drop may or may not be the deal.

What held

• The Helios thesis is unchanged. The 8-K is silent on revenue, guidance or strategy. Press reporting says World Labs builds "spatial intelligence" models (3D world generation, robotics simulation; first product "Marble"), that it trained on AMD GPUs, and that Fei-Fei Li becomes AMD EVP and Chief Scientist reporting to Lisa Su. None of that is in a filing.
• Taalas and FastFlowLM are still not primary-confirmed. See Lens 9 below.
• No other material filing since 2026-09-25. The submissions feed shows only this 8-K plus Forms 4 and 144 (2026-09-10 to 2026-09-17) since the prior dossier [SEC: data.sec.gov submissions CIK0000002488, fetched 2026-10-08]. The Q3 10-Q is not out.

Phase A — Understand the business

Lenses 1–4 — carried

Unchanged. See the previous dossier. World Labs is not yet consolidated and has no reported revenue in any AMD filing.

Phase B — Measure performance

Lenses 5–7 — carried

No new print. See the previous dossier.

Stock-Price Catalysts — re-run (one addition)

• New catalyst: World Labs closing. The share count is struck on the 10-day VWAP ending two trading days before close; the issue shows up in the 10-Q or 10-KForm 10-KA company’s audited annual report to the US regulator. The most complete thing it publishes. for the closing quarter. Watch the Q3 10-Q (~early Nov) for a subsequent-events note with the expected share count, any Ex-2.1 merger agreement, and any HSR/regulatory timing.
• Price note. The prior dossier gave ~$615 at the 2026-09-24 close. Yahoo has $629.26 on 09-24 and $614.61 on 09-23. Likely a one-day offset in the earlier source; recorded, not resolved.
• Since the prior dossier: $630.63 (09-25) → $645.86 (10-07), +2.4%.

Phase C — Judge people & books

Management — re-run (acquisitions)

The open question from 2026-09-25: verify Taalas and FastFlowLM from primary sources.

Plain reading: AMD's Q2 10-Q says only that it "completed acquisitions that were immaterial both individually and in aggregate" [SEC: 10-Q, 2026-08-05, 0000002488-26-000123, Note 5]. Small deals like Taalas and FastFlowLM can legally stay unnamed if they are immaterial, so absence from filings is not evidence they did not happen. It does mean their price and whether they were paid in stock or cash is not found in any primary source. The brief's framing that World Labs is "a third stock-funded deal" can only be half-checked: World Labs is stock-funded per the filing; the funding of Taalas and FastFlowLM is unknown. Fidelity funds holding Taalas shares is a possible later check: if their next N-PORT shows the line converted to AMD stock, that would be indirect primary evidence of a stock deal.

People. Fei-Fei Li to AMD as EVP and Chief Scientist. No Item 5.02 8-K has been filed for her appointment as of 2026-10-08 [SEC: submissions feed, 2026-10-08]; whether one is required depends on whether she becomes an executive officer.

Forensic Red Flags — re-run (one item)

• Disclosure light on an $8.2B deal. Filing only Item 3.02, with no merger agreement attached, is permitted but thin. AMD is very large, so $8.2B (~0.8% of market value) may sit below the significance test that would force a fuller filing. Watch for the agreement as an exhibit to the Q3 10-Q.
• Goodwill. An all-stock purchase of a pre-revenue research lab will land mostly in goodwill and intangibles, adding to the impairment exposure the 10-Q risk factors already flag [SEC: 10-Q, 2026-08-05, Item 1A]. Size unknown until the purchase-price allocation.
• Acquisition-related cost will run through the non-GAAP add-backs; watch the Q4 reconciliation.
• Everything else carried from the previous dossier Lens 10.

Phase D — Project & stress-test

Lenses 11–14 — carried

FY26/FY27 projections in the previous dossier Lens 11 are unchanged. At ~13M extra shares the FY27 per-share effect is under 1%, below the precision of the projection. Add one management question to Lens 14:

• N4. What does World Labs add to Data Center revenue or roadmap by 2027, what is the expected closing date and share count, and what did Taalas and FastFlowLM cost and how were they paid?

Shelf & provenance summary (this run)

• Added: filings/8-k-2026-09-28-world-labs.md (primary document text; no exhibits exist).
• Checked, nothing new: submissions feed since 2026-09-25 (only Forms 4/144 besides the 8-K); EDGAR full-text search for Taalas, FastFlowLM, World Labs.
• Not found in any primary source: World Labs closing date, the actual share count, the merger agreement text; Taalas and FastFlowLM price, funding and closing status.
• Still open from 2026-09-25: 10-K Item 3, Helios Q3 shipment, Q3 date on ir.amd.com, peer multiples, workbook rebuild, DB ingest.